Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 403 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Binocular Vision Suppression Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

NCT05911360
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
DTG/3TC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
50 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
24
States / cities
Phoenix, Arizona • Bakersfield, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 2:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Color-dependent Melatonin Suppression

NCT02936674
View directory record Official record
Conditions
Melatonin
Interventions
Light - standard, Light - alternate
Device
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Jul 23, 2026, 2:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

NCT02452424
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
Interventions
PLX3397, Pembrolizumab
Drug · Biological
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Jul 23, 2026, 2:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Validation of RespiLife for Detection of Respiratory Suppression

NCT03819023
View directory record Official record
Conditions
Respiration Disorders
Interventions
Respilife monitor
Diagnostic Test
Lead sponsor
Bioresp Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Burlingame, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Jul 23, 2026, 2:28 AM EDT
Terminated Phase 2 Interventional

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

NCT03245385
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Treatment with Halobetasol propionate 0.05% topical spray
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
12 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
North Hollywood, California • Pasadena, California • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 23, 2026, 2:28 AM EDT
Completed Phase 1 Interventional

Combination Drug Treatment of Pediatric HIV Infection

NCT00001818
View directory record Official record
Conditions
HIV Infection
Interventions
Hydroxyurea
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 2:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)

NCT04519970
View directory record Official record
Conditions
Hiv
Interventions
Case Management
Behavioral
Lead sponsor
Gregory Huhn
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Jul 23, 2026, 2:28 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation

NCT01421797
View directory record Official record
Conditions
Hyperandrogenemia, Polycystic Ovary Syndrome, Obesity
Interventions
Dexamethasone, Cortrosyn
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Jul 23, 2026, 2:28 AM EDT
Completed Phase 2 Interventional

Medical Treatment for Diamond Blackfan Anemia

NCT00001749
View directory record Official record
Conditions
Fanconi's Anemia, Hematologic Disease
Interventions
Antithymocyte globulin, Cyclosporine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 2:28 AM EDT
Completed Phase 3 Interventional

Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)

NCT00002224
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2011 · Synced Jul 23, 2026, 2:28 AM EDT
Terminated Phase 3 Interventional Results available

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

NCT00968968
View directory record Official record
Conditions
Cancer
Interventions
Lapatinib, Trastuzumab
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
112
States / cities
Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Jul 23, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study

NCT01043393
View directory record Official record
Conditions
Psoriasis
Interventions
Desoximetasone 0.25% spray
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Hot Springs, Arkansas • Albuquerque, New Mexico • Simpsonville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Jul 23, 2026, 2:28 AM EDT
Completed Phase 1 Interventional

A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042

NCT06525649
View directory record Official record
Conditions
Photosensitive Epilepsy, Epilepsy
Interventions
NPT 2042
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Little Rock, Arkansas • Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Jul 23, 2026, 2:28 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The Influence of Gonadal Hormone Suppression on Adipocyte Lineage and the Microbiome

NCT03396978
View directory record Official record
Conditions
Adipose Tissue, Microbiome, Menopause
Interventions
GnRHag
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Jul 23, 2026, 2:28 AM EDT
Completed Phase 1 Interventional

Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression

NCT00336778
View directory record Official record
Conditions
HIV Infections
Interventions
3TC, TDF, NLV
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Jul 23, 2026, 2:28 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Therapeutic Omegas for Triglyceride Suppression

NCT04349475
View directory record Official record
Conditions
Pregnancy
Interventions
Intervention Omega 3 Supplementation, Placebo Soybean Oil
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
0 Years to 39 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 23, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

NCT04743934
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Flibanserin 100 MG, Placebo, Androgen deprivation therapy
Drug
Lead sponsor
Andrew McDonald
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 2:28 AM EDT
Completed Early Phase 1 Interventional Results available

Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

NCT03507608
View directory record Official record
Conditions
Prostate Cancer
Interventions
Flutamide, Placebo
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Jul 23, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

NCT00460746
View directory record Official record
Conditions
HIV
Interventions
TMC125, Darunavir; Ritonavir
Drug
Lead sponsor
Tibotec, Inc
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Jul 23, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib to Treat Significant Complication of HSCT

NCT01929980
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation, Refractory Autoimmune Cytopenia(s)
Interventions
Bortezomib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Months to 29 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Jul 23, 2026, 2:28 AM EDT
Completed Not applicable Interventional

Technology Based Community Health Nursing to Improve Combination Anti-Retroviral Therapy (cART) Adherence and Virologic Suppression in Youth Living With HIV

NCT03600103
View directory record Official record
Conditions
HIV Infections, Adherence, Medication
Interventions
Tech2Check
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 25 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Jacksonville, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Jul 23, 2026, 2:28 AM EDT
Recruiting No phase listed Observational

Puberty Suppression and Cardiometabolic Health

NCT04482374
View directory record Official record
Conditions
Transgenderism, Insulin Sensitivity/Resistance, Endothelial Dysfunction, Vascular Stiffness
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years to 14 Years · Male only
Enrollment
30 participants
Timeline
2020 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jul 23, 2026, 2:28 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Case Management Dyad

NCT06162897
View directory record Official record
Conditions
HIV, Pre-exposure Prophylaxis, Case Management
Interventions
Dyadic Case Management
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 2:28 AM EDT
Withdrawn Early Phase 1 Interventional

Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

NCT01422096
View directory record Official record
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Leuprolide
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Jul 23, 2026, 2:28 AM EDT